# CKD-828 Primary Hypertension Trial(Dose-selection)

> **NCT01128322** · PHASE2 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 430 (estimated)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** S-Amlodipine, Telmisartan
- **DRUG:** S-Amlodipine
- **DRUG:** Telmisartan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01128322
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 430 (ESTIMATED)
- **Last updated:** 2011-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01128322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01128322, "CKD-828 Primary Hypertension Trial(Dose-selection)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01128322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*